Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550446 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 386
- Enrollment target
NCT00550446 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 386 participants.
The verdict
NCT00550446, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 386 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
Interventions
- DRUG Adalimumab
- DRUG CP-690,550
- DRUG CP-690-550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00550446
The ClinicalTrials.gov registry entry for NCT00550446 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Adalimumab is the first listed.
NCT00550446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00550446 about?
NCT00550446 is a clinical study titled "A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis". The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven wi...
What is the current status of trial NCT00550446?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2007-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00550446?
The interventions under investigation include: Adalimumab (DRUG), CP-690,550 (DRUG), CP-690-550 (DRUG).
Who is sponsoring clinical trial NCT00550446?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.